Kite Pharma Announces Patients With Relapsed or Refractory

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Kite Pharma Announces Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells

Phase 1 Clinical Trial Highlights:

  • 14 of 20 pediatric or young adult patients (70%) with relapsed or refractory ALL experienced a complete response.
  • 12 of the 20 patients (60%) achieved a minimal residual disease (MRD)-negative complete response.
  • 10 of the patients who had an MRD-negative complete response subsequently underwent hematopoietic stem-cell transplantation, and all 10 remained disease free upon 10-month follow-up.
  • The results have been published in the October 13, 2014 Issue of The Lancet

SANTA MONICA, Calif., Oct. 13, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq: KITE ), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the publication in The Lancet of clinical results demonstrating the potential to treat relapsed or refractory acute lymphoblastic leukemia (ALL) with an anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Kite's most advanced product candidate, KTE-C19, is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient's T cells to express a CAR that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.

The findings from a Phase 1 clinical trial conducted by the Pediatric Oncology Branch of the National Cancer Institute (NCI) demonstrated that administration of anti-CD19 CAR T cells resulted in a 70% complete response rate in 20 pediatric or young adult patients with relapsed or refractory ALL. Sixty percent of the 20 patients achieved an MRD-negative complete response. Ten of the patients who had an MRD-negative complete response subsequently underwent hematopoietic stem-cell transplantation (HSCT), and all 10 remained disease free with a median follow-up of 10 months. These and other findings from the Phase 1 study are being published in an article titled, "T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial," http://dx.doi.org/10.1016/S0140-6736(14)61403-3, which is appearing in the October 13, 2014 issue of The Lancet . Lead author on the article is Crystal L. Mackall, M.D., Head of Immunology Section and Chief of the Pediatric Oncology Branch at the National Cancer Institute.

Gary Schiller, M.D., F.A.C.P., Professor, Director, Hematological Malignancies/Stem Cell Transplantation Unit, David Geffen School of Medicine at UCLA, commented, "This article, the first publication of an intention-to-treat analysis from a completed clinical study of CD19-CAR therapy in pediatric and young adult patients with relapsed/refractory ALL, deepens our understanding of this important investigational approach. The results show that this treatment is feasible in many patients with ALL and can eradicate chemoresistant disease with an acceptable toxicity profile. Further, the findings demonstrate substantially higher response rates than seen in the literature for the most recently approved agent for refractory ALL. CD19-CAR therapy represents a potentially important new tool to address the urgent need for new treatment modalities in these patients."

The open-label, Phase 1 dose-escalation study enrolled patients aged 1-30 years. Prior to the study, all patients had been heavily pretreated for their disease. Patients received a conditioning regimen of chemotherapy (cyclophosphamide and fludarabine) followed by a single infusion of one of two dose levels of anti-CD19-CAR T cells. The CAR-expressing T cells were produced from each patient's own peripheral blood mononuclear cells (PBMCs), modified using a gammaretroviral vector encoding the CAR, as well as a CD28 costimulatory moiety. After the dose-escalation phase, an expansion cohort was treated at the maximum tolerated dose. Pursuant to the study protocol, patients are continuing to be monitored.

As seen in other studies, infusion of anti-CD19 CAR T cells was associated with significant, acute toxicities, including fever, hypokalemia, and transient neurological deficits. All toxicities were fully reversible.

David Chang, M.D., Ph.D., Kite Pharma's Executive Vice President, Research and Development, and Chief Medical Officer, stated, "The findings of the study reported in the Lancet further support promising results with our CD19-CAR construct in other blood cancers, such as in patients with aggressive, refractory non-Hodgkin's lymphoma. Toxicities were readily managed in the Lancet study, and the findings provided important information on defining response rates and maximum tolerated dose, as well as affirming the feasibility of generating CD19-CAR T cells in this heavily pretreated patient population."

Kite previously announced positive results in chemotherapy-refractory diffuse large B-cell lymphoma (DLBCL) in a study conducted under the auspices of Kite and the Surgery Branch of the NCI, led by Steven A. Rosenberg, M.D., Ph.D. Kite and Dr. Rosenberg's team are collaborating under a Cooperative Research and Development Agreement (CRADA) for the research and development of eACT™-based product candidates for the treatment of multiple cancer indications.

"We are greatly encouraged by the continuing strong results from the NCI using our proprietary CD19-CAR construct in very sick patient groups," commented Arie Belldegrun, M.D., FACS, Kite's President and Chief Executive Officer. "The importance of a new approach to treating advanced cancer in the youngest patients cannot be over-emphasized."

Dr. Belldegrun continued, "As previously reported, Kite plans to file an IND this year to initiate a Phase 1-2 single-arm multicenter clinical trial of its lead CD19-CAR therapy, KTE-C19, in patients with DLBCL who have failed two or more lines of therapy. For the trial, we will manufacture product using our streamlined and rapid production process. We are excited to advance this promising therapy and anticipate initiating our first Kite-sponsored study next year."

About Kite Pharma

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com .

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success and timing of the ongoing and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation of our clinical trial of KTE-C19; the ability and willingness of the NCI to continue research and development activities relating to eACT™ pursuant to the CRADA; our expectations regarding the clinical effectiveness and safety of our product candidates and results of the NCI's clinical trials; our ability to manufacture our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates and advancing a clinical trial of KTE-C19; and our ability to protect our proprietary technology and enforce our intellectual property rights. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission, including without limitation in its Form 10-Q for the quarter ended June 30, 2014. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Kite Contact: Cynthia M. Butitta Chief Financial Officer and Chief Operating Officer 310-824-9999 For Media: Justin Jackson For Investor Inquiries: Kimberly Minarovich Burns McClellan (212) 213-0006

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 85

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 65

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 38

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 30

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 34

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
ISDN Holdings: Leading APAC Automation with Innovation

Updated Category News Views 68

Pioneering Automation Intelligence in APAC Not every day you hear a company quietly revolutionizing an entire industry's landscape—but ISDN Holdings Limited is one of those rare players. Recognized by Frost & Sullivan for its top-tier customer value leadership, ISDN is making waves across the Asia-Pacific's industrial scene with its integrated industrial automation...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 105

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Max y Noelia Explore Trade at 9th CIIE in Shanghai

Updated Category News Views 23

Influencers at the Heart of Global Trade Exploration Makin' their debut on the big stage of the 9th China International Import Expo (CIIE), Mexican influencers Max y Noelia found themselves caught in a whirlwind of trade and cultural exchanges over in Shanghai. These digital mavens aren't just snapping selfies. Nope, they're capturing the very essence of international...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 189

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 67

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading

Top 5 Most Recently Viewed Articles

Butterfly Network and Rutgers Study Show Impact of POCUS

Updated Category News Views 129

Revolutionizing Hospital Care with POCUS Technology BURLINGTON, Mass. & NEW YORK-- Butterfly Network, Inc. (NYSE: BFLY), a pioneering digital health company, has launched a significant study in collaboration with Rutgers Robert Wood Johnson Medical School. This research emphasizes the transformative influence of point-of-care ultrasound (POCUS) technology on patient...

Continue Reading
Civista Bancshares Increases Quarterly Dividend to 17 Cents

Updated Category News Views 127

Civista Bancshares Boosts Quarterly Dividend Payments Civista Bancshares, Inc. (NASDAQ: CIVB), the financial cornerstone of Civista Bank, has made a noteworthy announcement regarding its quarterly dividends. The Board of Directors has approved a hike in the dividend to 17 cents per common share. This increment of 1 cent reflects the company's commitment to returning value...

Continue Reading
Argentinians Traveling Abroad for Cheaper Goods and Prices

Updated Category News Views 233

Argentinians Seeking Affordable Goods Abroad Amid rising domestic prices, it seems that many Argentinians are turning their eyes overseas in search of better deals on consumer goods. This trend has become evident as locals prioritize travel to countries like Brazil and Chile, where prices are significantly lower. The ongoing economic situation in Argentina, characterized...

Continue Reading
RomReal's Annual Report Insights and Audit Overview for 2024

Updated Category News Views 229

RomReal's Performance Overview for 2024 RomReal has been navigating a dynamic market landscape, with its annual report revealing insights into the company's financial health and operational resilience. The company has shown remarkable adaptability in the face of fluctuations within the industry, contributing to its performance in the 2024 fiscal year. This overview sheds...

Continue Reading
Microsoft's Flexible Work Policy: A New Era for Employees

Updated Category News Views 303

Microsoft rolled out a major statement back in 2024 that they're not gonna enforce a mandatory return-to-office unless they see productivity tank. Bigwigs at the company made it clear that for now, keeping things flexible is the name of the game. And why wouldn’t it be? With new hires flocking to companies that let them work from home, Microsoft knows they need to play...

Continue Reading